AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8436149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 2.5 mg per day
Number of subjects: 18
Study 8436149 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg per day
Number of subjects: 18
Study 8436149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2936370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (10 mg)
Number of subjects: 20
Study 2936370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (0.6 mg)
Number of subjects: 20
Study 2936370 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide
Number of subjects: 20
Study 2936370 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nebulized salbutamol and ipratropium bromide
Number of subjects: 20
Study 31627965 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching with mobilization (SWM)
Number of subjects: 40
Study 31627965 — intervention group
Group type: COMPARATOR
Intervention: Stretching alone
Number of subjects: 40
Study 30355358 — intervention group
Group type: EXPERIMENTAL
Intervention: Store-and-forward teledermatology in GP practices
Number of subjects: 260
Study 30355358 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 260
Study 28008244 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110 μg/50 μg
Number of subjects: 1263
Study 28008244 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY)
Number of subjects: 1263
Study 28008244 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (SFC) 50 μg/500 μg
Number of subjects: 1263
Study 24916694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 103
Study 24916694 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Fulvestrant
Number of subjects: 103
Study 22864943 — intervention group
Group type: COMPARATOR
Intervention: Curettage adenoidectomy (CA)
Number of subjects: 53
Study 22864943 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral power‐assisted endoscopic adenoidectomy (PAEA)
Number of subjects: 53
Study 20397858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hold-Relax (HR) stretching technique
Number of subjects: 35
Study 20397858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hold-Relax-Antagonist Contraction (HR-AC) stretching technique
Number of subjects: 35
Study 20397858 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG activation after HR-AC procedure
Number of subjects: 35
Study 18498909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with olmesartan medoxomil (OM) and amlodipine besylate (AML)
Number of subjects: 1940
Study 18498909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with OM and AML
Number of subjects: 1940
Study 18498909 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan medoxomil (OM) monotherapy
Number of subjects: 1940
Study 18498909 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate (AML) monotherapy
Number of subjects: 1940
Study 18498909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1940
Study 18498909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with OM/AML 20/10 mg and 40/10 mg
Number of subjects: 1940
Study 15660633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Interview (CI) for children who watched a film about a fakir (n=19)
Number of subjects: 58
Study 15660633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Interview (CI) for children who made up a story about a fakir (n=21)
Number of subjects: 58
Study 15660633 — intervention group
Group type: COMPARATOR
Intervention: Structured Interview (SI) for children who made up a story about a fakir (n=18)
Number of subjects: 58
Study 12526069 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg/day for 3 days
Number of subjects: 110
Study 12526069 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 50 mg/kg/day for 14 days
Number of subjects: 110
Study 12526069 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 75 mg/kg/day for 7 days
Number of subjects: 110
Study 10536434 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% topical solution for 1 week
Number of subjects: 429
Study 10536434 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 1% topical solution for 4 weeks
Number of subjects: 429
Study 10536434 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% solution (subgroup without protocol violation)
Number of subjects: 429
Study 10536434 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 1% solution (subgroup without protocol violation)
Number of subjects: 429
Study 10536434 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine group
Number of subjects: 429
Study 10536434 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole group
Number of subjects: 429
Study 8871416 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy plus the nicotine patch (BTP)
Number of subjects: 64
Study 8871416 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy alone (BT)
Number of subjects: 64
Study 1649867 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral potassium supplements
Number of subjects: 586
Study 6366132 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous therapy (MTX 200 mg/m2 IV and 5-FU 600 mg/m2 IV)
Number of subjects: 79
Study 6366132 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (MTX 200 mg/m2 IV followed by 5-FU 600 mg/m2 IV after one hour)
Number of subjects: 79
Study 6366132 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous therapy (MTX 200 mg/m2 IV and 5-FU 600 mg/m2 IV) among stage III patients
Number of subjects: 79
Study 6366132 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (MTX 200 mg/m2 IV followed by 5-FU 600 mg/m2 IV after one hour) among stage III patients
Number of subjects: 79
Study 31529590 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-9375 (0.3 to 1.8 mg/kg)
Number of subjects: 308
Study 31529590 — intervention group
Group type: COMPARATOR
Intervention: Apixaban (2.5 mg twice daily)
Number of subjects: 308
Study 31529590 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-9375
Number of subjects: 308
Study 31529590 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 308
Study 29768313 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg orally)
Number of subjects: 88
Study 29768313 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg orally)
Number of subjects: 88
Study 26950829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice daily (BID)
Number of subjects: 73
Study 26950829 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin 5 mg once daily (QD)
Number of subjects: 73
Study 26950829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 73
Study 26950829 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin
Number of subjects: 73
Study 24502911 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D virtual reality‐based program, six sessions of virtual game
Number of subjects: 0
Study 24502911 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study 22094124 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0
Study 22094124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21702254 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg midazolam as pre‐medication 1 hour preoperatively
Number of subjects: 60
Study 21702254 — intervention group
Group type: COMPARATOR
Intervention: Placebo as pre‐medication
Number of subjects: 60
Study 17339813 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention, frequency 3 to 5 times per week, duration 45 to 60 minutes, total period 12 to 24 weeks.
Number of subjects: 16
Study 17339813 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention, frequency 3 to 5 times per week, duration 45 to 60 minutes, total period 12 to 24 weeks.
Number of subjects: 16
Study 17339813 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication intervention, frequency 3 to 5 times per week, duration 45 to 60 minutes, total period 12 to 24 weeks.
Number of subjects: 16
Study 17339813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention, frequency 3 to 5 times per week, duration 45 to 60 minutes, total period 12 to 24 weeks.
Number of subjects: 16
Study 17339813 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 16
Study 16382062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI
Number of subjects: 427
Study 16382062 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 427
Study 16382062 — intervention group
Group type: COMPARATOR
Intervention: Repeated thrombolysis
Number of subjects: 427
Study 16382062 — intervention group
Group type: COMPARATOR
Intervention: Repeated thrombolysis vs Conservative therapy
Number of subjects: 427
Study 16382062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI vs Repeated thrombolysis
Number of subjects: 427
Study 16382062 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PCI vs Conservative therapy
Number of subjects: 427
Study 12073949 — intervention group
Group type: EXPERIMENTAL
Intervention: External jugular venous pressure
Number of subjects: 20
Study 12073949 — intervention group
Group type: COMPARATOR
Intervention: Central venous pressure
Number of subjects: 20
Study 9856539 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking milk (300 ml)
Number of subjects: 27
Study 9856539 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking water (300 ml)
Number of subjects: 27
Study 9856539 — intervention group
Group type: COMPARATOR
Intervention: No drink (control)
Number of subjects: 27
Study 7796718 — intervention group
Group type: EXPERIMENTAL
Intervention: Current users of anabolic steroids
Number of subjects: 46
Study 7796718 — intervention group
Group type: COMPARATOR
Intervention: Former users of anabolic steroids
Number of subjects: 46
Study 7796718 — intervention group
Group type: COMPARATOR
Intervention: Non-users of anabolic steroids
Number of subjects: 46
Study 2131953 — intervention group
Group type: COMPARATOR
Intervention: Alginate-antacid (1 tablet to be chewed 30 min after each meal and at bed time)
Number of subjects: 49
Study 2131953 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (1 mg/kg before supper at 7 pm)
Number of subjects: 49
Study 374847 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel pilocarpin polymeric salt eye drops
Number of subjects: 30
Study 374847 — intervention group
Group type: COMPARATOR
Intervention: Commercial aqueous pilocarpin solution
Number of subjects: 30
Study 30614850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine 0.3 mg
Number of subjects: 14
Study 30614850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27557443 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (8-11 sessions of Electromyography biofeedback, Vasoconstriction-/Vasodilatation training, or a combination)
Number of subjects: 18
Study 27557443 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 18
Study 25942459 — intervention group
Group type: EXPERIMENTAL
Intervention: cART with tenofovir/emtricitabine plus ritonavir-boosted atazanavir
Number of subjects: 48
Study 25033901 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorized injector (group II)
Number of subjects: 62
Study 25033901 — intervention group
Group type: COMPARATOR
Intervention: Manual injector (group I)
Number of subjects: 62
Study 22224655 — intervention group
Group type: COMPARATOR
Intervention: Curcumin (L-D+)
Number of subjects: 13
Study 22224655 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (L+D+)
Number of subjects: 13
Study 19155765 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 0
Study 19155765 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 17706718 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrusor injection of 100 U botulinum toxin type A
Number of subjects: 45
Study 17706718 — intervention group
Group type: EXPERIMENTAL
Intervention: Suburothelial injection of 100 U botulinum toxin type A
Number of subjects: 45
Study 17706718 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder base injection of 100 U botulinum toxin type A
Number of subjects: 45
Study 15837759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 59
Study 15837759 — intervention group
Group type: COMPARATOR
Intervention: Serum creatinine
Number of subjects: 59
Study 15837759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal body weight (IBW)
Number of subjects: 59
Study 15837759 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 59
Study 15837759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C level
Number of subjects: 59
Study 11782988 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal dystonia patients
Number of subjects: 7
Study 11782988 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 7
Study 9839106 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/day)
Number of subjects: 30
Study 9839106 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 mg/day)
Number of subjects: 30
Study 7988584 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 90
Study 7988584 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask with nasopharyngeal airway
Number of subjects: 90
Study 7988584 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask alone
Number of subjects: 90
Study 2724028 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% sanguinaria-0.05% zinc chloride dentifrice
Number of subjects: 59
Study 2724028 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24% sodium fluoride dentifrice
Number of subjects: 59
Study 2724028 — intervention group
Group type: COMPARATOR
Intervention: 0.05% NaF solution (control)
Number of subjects: 59
Study 31625761 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to parks
Number of subjects: 978
Study 31625761 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of park stay
Number of subjects: 978
Study 31625761 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of physical activity
Number of subjects: 978
Study 31625761 — intervention group
Group type: EXPERIMENTAL
Intervention: Park access
Number of subjects: 978
Study 31625761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular diseases
Number of subjects: 978
Study 31625761 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 978
Study 29124991 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance treatment
Number of subjects: 65
Study 27114587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate during interim maintenance 1
Number of subjects: 3154
Study 27114587 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate
Number of subjects: 3154
Study 27114587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and high-dose methotrexate
Number of subjects: 3154
Study 27114587 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone during induction
Number of subjects: 3154
Study 24533385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoid obliteration with cartilage, bone dust, hydroxyapetite, and Singapore swing
Number of subjects: 40
Study 24533385 — intervention group
Group type: COMPARATOR
Intervention: Open mastoid cavity (control group)
Number of subjects: 40
Study 24533385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoid obliteration with bone dust and Singapore swing
Number of subjects: 40
Study 24533385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastoid obliteration with cartilage and hydroxyapetite
Number of subjects: 40
Study 23535292 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg bid BDP + RTV for 28 days
Number of subjects: 30
Study 23535292 — intervention group
Group type: EXPERIMENTAL
Intervention: 600/100 mg bid BDP + DRV/r for 28 days
Number of subjects: 30
Study 23535292 — intervention group
Group type: COMPARATOR
Intervention: BDP alone for 28 days (Control)
Number of subjects: 30
Study 23535292 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 19853533 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125 brachytherapy alone (144 Gy)
Number of subjects: 110
Study 19853533 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125 brachytherapy as a boost after 45-Gy EBRT (108 Gy)
Number of subjects: 110
Study 19853533 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT with rV(100%) >= 0.05 cc
Number of subjects: 110
Study 19853533 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT with rV(100%) < 0.05 cc
Number of subjects: 110
Study 19853533 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT with dose to hottest 0.1 cc
Number of subjects: 110
Study 19853533 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT with dose to hottest 1%
Number of subjects: 110
Study 19853533 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT with dose to hottest 3%
Number of subjects: 110
Study 18212693 — intervention group
Group type: COMPARATOR
Intervention: Group corticosteroid (Group S) received 6-methylprednisolone 15 mg/kg IV 60 min before induction.
Number of subjects: 60
Study 18212693 — intervention group
Group type: EXPERIMENTAL
Intervention: Group TEA+corticosteroid (Group TEA+S) received 20 mg bupivacaine in bolus 60 min before induction followed by 20 mg/h bupivacaine infusion intraoperatively and postoperatively via epidural catheter.
Number of subjects: 60
Study 18212693 — intervention group
Group type: EXPERIMENTAL
Intervention: Group TEA (Group TEA) received 20 mg bupivacaine in bolus 60 min before induction followed by 20 mg/h bupivacaine infusion intraoperatively and postoperatively via epidural catheter.
Number of subjects: 60
Study 18212693 — intervention group
Group type: COMPARATOR
Intervention: Group control (Group C) received neither preinduction TEA nor a preinduction steroid.
Number of subjects: 60
Study 17212187 — intervention group
Group type: EXPERIMENTAL
Intervention: Early psychological interventions
Number of subjects: 0
Study 17212187 — intervention group
Group type: EXPERIMENTAL
Intervention: Current early psychological interventions
Number of subjects: 0
Study 17212187 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled studies
Number of subjects: 0
Study 17212187 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of intervention strategies from adults
Number of subjects: 0
Study 17212187 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of developmental aspects
Number of subjects: 0
Study 14672294 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat
Number of subjects: 554
Study 14672294 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 554
Study 14672294 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy
Number of subjects: 554
Study 14672294 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 554
Study 11164205 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry powder of mannitol
Number of subjects: 2
Study 9128319 — intervention group
Group type: EXPERIMENTAL
Intervention: MISO TID (200 microg three times daily)
Number of subjects: 70
Study 9128319 — intervention group
Group type: EXPERIMENTAL
Intervention: MISO BID (200 microg two times daily)
Number of subjects: 70
Study 9128319 — intervention group
Group type: COMPARATOR
Intervention: RAN (150 mg twice daily)
Number of subjects: 70
Study 7949692 — intervention group
Group type: EXPERIMENTAL
Intervention: heliotropin with humidified air (n = 20)
Number of subjects: 57
Study 7949692 — intervention group
Group type: COMPARATOR
Intervention: humidified air alone (n = 37)
Number of subjects: 57
Study 3622786 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine in the Foley drainage bag
Number of subjects: 56
Study 3622786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Betadine)
Number of subjects: 56
Study 29742273 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational manual for childbirth companions
Number of subjects: 65
Study 28131706 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-managed automatic therapy for atrial tachycardia or fibrillation (AT/AF)
Number of subjects: 420
Study 28131706 — intervention group
Group type: COMPARATOR
Intervention: In-hospital approach for treatment of symptomatic AT/AF
Number of subjects: 420
Study 26780278 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3
Number of subjects: 90
Study 26780278 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3 plus 500 mg calcium
Number of subjects: 90
Study 26780278 — intervention group
Group type: COMPARATOR
Intervention: Plain yogurt drink (control group)
Number of subjects: 90
Study 23278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of tenofovir dipivoxil fumarate 150 mg
Number of subjects: 0
Study 23278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of tenofovir dipivoxil fumarate 300 mg
Number of subjects: 0
Study 23278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of tenofovir dipivoxil fumarate 600 mg
Number of subjects: 0
Study 23278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of tenofovir dipivoxil fumarate 300 mg
Number of subjects: 0
Study 23278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of tenofovir dipivoxil fumarate 300 mg with high-fat meal
Number of subjects: 0
Study 23278367 — intervention group
Group type: COMPARATOR
Intervention: Single dose of tenofovir dipivoxil fumarate 300 mg fasting vs multiple doses
Number of subjects: 0
Study 23278367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of tenofovir dipivoxil fumarate 300 mg with food
Number of subjects: 0
Study 21843215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/propofol (ketofol)
Number of subjects: 62
Study 21843215 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/fentanyl (MF)
Number of subjects: 62
Study 18283141 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail communication (group E)
Number of subjects: 100